General form of registration statement for all companies including face-amount certificate companies

COMMITMENTS AND CONTINGENCIES (Details Narrative)

v3.21.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Apr. 30, 2017
Sep. 30, 2021
Sep. 30, 2021
Dec. 31, 2020
Dec. 31, 2018
Loss Contingencies [Line Items]          
Drug development costs to service   $ 166,929 $ 388,336    
Number of warrants         6,000
Warrant exercise price         $ 1.00
License Agreement [Member] | QSAM Therapeutics Inc [Member]          
Loss Contingencies [Line Items]          
Payments for milestone $ 60,000     $ 60,000  
Other expense reimbursements     60,000 $ 60,000  
Equity method investment ownership percentage 5.00%     5.00%  
Royalty percentage 4.50%     4.50%  
Consulting fee     8,500    
Payment for license fees     $ 60,000    
Total cost,involved in connection with license       $ 120,000  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Upon Commercialization [Member]          
Loss Contingencies [Line Items]          
Other expense reimbursements $ 1,500,000        
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Drug Development Costs Paid To Service Providers [Member]          
Loss Contingencies [Line Items]          
Total cost,involved in connection with license       86,943  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Maximum [Member]          
Loss Contingencies [Line Items]          
Other expense reimbursements $ 150,000     $ 150,000  
Royalty percentage 50.00%     50.00%  
License Agreement [Member] | QSAM Therapeutics Inc [Member] | Minimum [Member]          
Loss Contingencies [Line Items]          
Royalty percentage 10.00%        
Services Agreement [Member]          
Loss Contingencies [Line Items]          
Number of warrants         6,000
Warrant term outstanding         five-year term
Warrant exercise price         $ 1.00